TY - JOUR T1 - Rheumatoid Arthritis, Statin Indication and Lipid Goals: Analysis According to Different Recommendations JO - Reumatología Clínica T2 - AU - Masson,Walter AU - Rossi,Emiliano AU - Alvarado,Rodolfo N. AU - Cornejo-Peña,Guillermo AU - Damonte,Juan I. AU - Fiorini,Norberto AU - Mora-Crespo,Lorena M. AU - Tobar-Jaramillo,Mayra A. AU - Scolnik,Marina SN - 1699258X M3 - 10.1016/j.reuma.2021.02.002 DO - 10.1016/j.reuma.2021.02.002 UR - https://reumatologiaclinica.org/es-rheumatoid-arthritis-statin-indication-lipid-articulo-S1699258X21000565 AB - BackgroundDifferent strategies have been proposed for the cardiovascular risk management of patients with rheumatoid arthritis (RA). Objectives(1) To estimate the cardiovascular risk by different strategies in RA patients, analyzing which proportion of patients would be candidates to receive statin therapy; (2) to identify how many patients meet the recommended lipid goals. MethodsA cross-sectional study was performed from a secondary database. The QRISK-3 score, the Framingham score (adjusted for a multiplying factor×1.5), the ASCVD calculator and the SCORE calculator were estimated. The indications for statin therapy according to NICE, Argentine Consensus, ACC/AHA, and new European guidelines were analyzed. The recommended LDL-C goals were analyzed. ResultsA total of 420 patients were included. In total, 24.7% and 48.7% of patients in primary and secondary prevention were receiving statins, respectively. Only 19.4% of patients with cardiovascular history received high intensity statins. Applying the ACC/AHA guidelines (based on ASCVD score), the Argentine Consensuses (based on adjusted Framingham score), the NICE guidelines (based on QRISK-3) and European recommendations (based on SCORE), 26.9%, 26.5%, 41.1% and 18.2% of the population were eligible for statin therapy, respectively. Following the new European recommendations, 50.0%, 46.2% and 15.9% of the patients with low-moderate, high or very high risk achieved the suggested lipid goals. ConclusionApplying four strategies for lipid management in our population, the cardiovascular risk stratification and the indication for statins were different. A significant gap was observed when comparing the expected and observed statin indication, with few patients achieving the LDL-C goals. ER -